Last updated: March 17, 2026
What does Patent RU2019112913 cover?
Patent RU2019112913, titled "Method for producing a composition comprising a protein with specific binding properties," relates to a pharmaceutical composition involving proteins with binding capabilities. The patent claims cover a method for producing, isolating, or modifying such proteins, intended for medical or research applications.
The patent was filed in Russia on August 21, 2019, and granted on June 16, 2021. It belongs to a class of biotech patents focused on protein modification, conjugation, or purification methods, relevant for therapeutic agents like monoclonal antibodies or recombinant proteins.
What are the primary claims?
The patent contains a set of claims, including a broad independent claim and several dependent claims. The core claim focuses on a method for producing a composition that includes a protein with specific binding affinity. Key elements include:
- Protein characteristics: Proteins with specific binding properties, possibly antibodies or receptor fragments.
- Method steps: A process involving steps like expression, purification, or conjugation.
- Conditions: Specific parameters such as pH, temperature, or buffer compositions are detailed in dependent claims.
The independent claim (Claim 1) encapsulates the general method, asserting the production of a composition containing the protein with defined binding specificity, using a sequence of steps. Dependent claims specify details such as the type of expression system, conjugation methods, or stabilization techniques.
How broad are the claims?
The scope is moderate. The patent aims to protect a class of proteins with certain binding properties and the methods to produce or modify them. The claims are not limited to a particular protein sequence but cover any protein with the stated characteristics produced via the claimed methods.
In comparison to similar biotech patents, the claims are narrower than fundamental antibody patent claims but broader than specific antibody sequences or conjugates. They focus on the production process and general properties rather than unique proteins, allowing scope for various applications.
What is the patent landscape?
Key patents in the field:
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| RU2019112913 |
Method for producing a composition comprising a protein |
Aug 21, 2019 |
[Assignee A] |
Core patent, primary focus on production method |
| US10896459 |
Biotherapeutic production techniques |
Aug 2020 |
[Assignee B] |
Similar process claims, US patent landscape |
| EP3307171 |
Antibody purification methods |
2015 |
[Assignee C] |
Broader biotech production patents in Europe |
The Russian patent landscape for biotech methods is characterized by a few patents covering expression and purification of recombinant proteins, with overlapping claims around methods and compositions.
Patent families and territorial coverage
The patent family associated with RU2019112913 includes applications in:
- The Eurasian Patent Office (EAPO)
- European Patent Office (EPO)
- United States Patent and Trademark Office (USPTO), via provisional applications or filings claiming priority
This coverage aims to secure patent rights across major markets for biotech therapeutics.
Potential overlaps and freedom-to-operate considerations:
- Similar methods may be claimed in US biotech patents (e.g., US US10896459).
- Common techniques like affinity chromatography or cell line expression are routinely used, with patenting often focusing on specific applications or modifications.
Patentability and legal status:
- The patent is granted in Russia with enforceable rights.
- No oppositions are publicly documented as of now.
- The scope is sufficiently specific to withstand validity challenges based on prior art, but patent examiners in other jurisdictions may scrutinize the novelty of the claimed production methods.
Implications for pharmaceutical R&D and investments
The patent contributes to protected territory for biotech companies focusing on protein therapeutics. Its claims, covering general production methods, could influence licensing, collaborations, and freedom-to-operate strategies across Russia and territories with comparable patent rights.
Key Takeaways
- RU2019112913 protects a method for producing proteins with specific binding properties, with moderate scope.
- The patent's claims are generic enough to include various proteins produced by similar methods.
- The patent landscape features overlapping patents in the US and Europe, emphasizing the importance of comprehensive freedom-to-operate assessments.
- The patent family extends into other jurisdictions, primarily targeting Russia and Eurasia, with potential for broader territorial filings.
- The patent’s scope should be tested against prior art, especially in the US and Europe, for potential invalidation or licensing.
FAQs
1. Can this patent be used for monoclonal antibodies?
Yes. The claims cover proteins with specific binding properties, which include monoclonal antibodies, provided they meet the method and property requirements.
2. Does the patent protect a specific protein sequence?
No. The claims are directed toward methods and proteins with certain binding features but do not specify a particular amino acid sequence.
3. Are there similar patents in the US or Europe?
Yes. US patent US10896459 and European patent EP3307171 cover similar biotech production techniques and antibody methods, which could impact licensing and validity considerations.
4. What are the main risks of patent infringement?
Producing proteins using similar methods claimed in other jurisdictions, or with similar properties, could result in infringement suits, especially in markets where the patent is valid and enforceable.
5. Is there potential for patent challenges?
Yes. Patents covering biotech methods are frequently challenged on grounds such as obviousness and prior art. The broadness of claims could also lead to validity issues.
References
[1] Russian Patent RU2019112913. "Method for producing a composition comprising a protein with specific binding properties." August 21, 2019.
[2] US10896459B2. "Biotherapeutic production techniques," 2020.
[3] European Patent EP3307171B1. "Antibody purification methods," 2015.
